Search research articles
Contact Us
Filters
Showing results (11-20 of 33) with videos related to
Page
of 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 1999
Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion
L H Sehn, E P Alyea, E Weller, et al.
Bone Marrow Transplantation
|
March 29, 2000
Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion
E Orsini, E P Alyea, R Schlossman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1995
Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia
G Pichert, D C Roy, R Gonin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 5, 2000
Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma
E Orsini, E P Alyea, A Chillemi, et al.
Transplantation
|
May 26, 2001
A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells
E Zorn, E Orsini, C J Wu, et al.
Bone Marrow Transplantation
|
June 15, 2007
Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy
A M Saito, D Zahrieh, C Cutler, et al.
The Journal of Clinical Investigation
|
August 15, 1997
Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion
E J Claret, E P Alyea, E Orsini, et al.
Blood
|
June 20, 1998
Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
E P Alyea, R J Soiffer, C Canning, et al.
The Journal of Clinical Investigation
|
September 7, 2000
Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia
C J Wu, X F Yang, S McLaughlin, et al.
Bone Marrow Transplantation
|
February 16, 2010
Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy
P Armand, H T Kim, E Mayer, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 33) with videos related to
Sort By:
Page
of 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 1999
Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion
L H Sehn, E P Alyea, E Weller, et al.
Bone Marrow Transplantation
|
March 29, 2000
Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion
E Orsini, E P Alyea, R Schlossman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1995
Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia
G Pichert, D C Roy, R Gonin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 5, 2000
Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma
E Orsini, E P Alyea, A Chillemi, et al.
Transplantation
|
May 26, 2001
A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells
E Zorn, E Orsini, C J Wu, et al.
Bone Marrow Transplantation
|
June 15, 2007
Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy
A M Saito, D Zahrieh, C Cutler, et al.
The Journal of Clinical Investigation
|
August 15, 1997
Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion
E J Claret, E P Alyea, E Orsini, et al.
Blood
|
June 20, 1998
Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
E P Alyea, R J Soiffer, C Canning, et al.
The Journal of Clinical Investigation
|
September 7, 2000
Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia
C J Wu, X F Yang, S McLaughlin, et al.
Bone Marrow Transplantation
|
February 16, 2010
Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy
P Armand, H T Kim, E Mayer, et al.
Page
of 4